Candel Therapeutics (CADL) Accumulated Expenses (2020 - 2025)

Candel Therapeutics' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $3.4 million for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 11.39% year-over-year to $3.4 million; the TTM figure through Dec 2025 stood at $3.4 million (up 11.39% YoY), while the FY2025 annual figure was $3.4 million, up 11.39% from the prior year.
• Accumulated Expenses came in at $3.4 million for Q4 2025 at Candel Therapeutics, down from $5.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $5.1 million in Q3 2025 to a low of $1.0 million in Q1 2025.
• A 5-year average of $3.0 million and a median of $3.2 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 243.08% in 2022 and tumbled 63.24% in 2025, its largest moves.
• Candel Therapeutics' Accumulated Expenses stood at $2.1 million in 2021, then soared by 125.33% to $4.7 million in 2022, then fell by 7.77% to $4.4 million in 2023, then sank by 30.26% to $3.0 million in 2024, then increased by 11.39% to $3.4 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.4 million, $5.1 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison